Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share
Apogee lost more money per share than experts thought it would, though it was only slightly worse than last quarter. When a company's losses are bigger than expected, it can make investors nervous about how fast the company is spending cash.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.